Targeting Innate Immunity in Glioma Therapy
Currently, there is a lack of effective therapies for the majority of glioblastomas (GBMs), the most common and malignant primary brain tumor. While immunotherapies have shown promise in treating various types of cancers, they have had limited success in improving the overall survival of GBM patient...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/2/947 |
| _version_ | 1797339821920747520 |
|---|---|
| author | Andrew G. Gillard Dong Ho Shin Lethan A. Hampton Andres Lopez-Rivas Akhila Parthasarathy Juan Fueyo Candelaria Gomez-Manzano |
| author_facet | Andrew G. Gillard Dong Ho Shin Lethan A. Hampton Andres Lopez-Rivas Akhila Parthasarathy Juan Fueyo Candelaria Gomez-Manzano |
| author_sort | Andrew G. Gillard |
| collection | DOAJ |
| description | Currently, there is a lack of effective therapies for the majority of glioblastomas (GBMs), the most common and malignant primary brain tumor. While immunotherapies have shown promise in treating various types of cancers, they have had limited success in improving the overall survival of GBM patients. Therefore, advancing GBM treatment requires a deeper understanding of the molecular and cellular mechanisms that cause resistance to immunotherapy. Further insights into the innate immune response are crucial for developing more potent treatments for brain tumors. Our review provides a brief overview of innate immunity. In addition, we provide a discussion of current therapies aimed at boosting the innate immunity in gliomas. These approaches encompass strategies to activate Toll-like receptors, induce stress responses, enhance the innate immune response, leverage interferon type-I therapy, therapeutic antibodies, immune checkpoint antibodies, natural killer (NK) cells, and oncolytic virotherapy, and manipulate the microbiome. Both preclinical and clinical studies indicate that a better understanding of the mechanisms governing the innate immune response in GBM could enhance immunotherapy and reinforce the effects of chemotherapy and radiotherapy. Consequently, a more comprehensive understanding of the innate immune response against cancer should lead to better prognoses and increased overall survival for GBM patients. |
| first_indexed | 2024-03-08T09:53:56Z |
| format | Article |
| id | doaj.art-87e1f908e9164d93abd7fef33949545b |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-08T09:53:56Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-87e1f908e9164d93abd7fef33949545b2024-01-29T13:55:44ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672024-01-0125294710.3390/ijms25020947Targeting Innate Immunity in Glioma TherapyAndrew G. Gillard0Dong Ho Shin1Lethan A. Hampton2Andres Lopez-Rivas3Akhila Parthasarathy4Juan Fueyo5Candelaria Gomez-Manzano6Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USACurrently, there is a lack of effective therapies for the majority of glioblastomas (GBMs), the most common and malignant primary brain tumor. While immunotherapies have shown promise in treating various types of cancers, they have had limited success in improving the overall survival of GBM patients. Therefore, advancing GBM treatment requires a deeper understanding of the molecular and cellular mechanisms that cause resistance to immunotherapy. Further insights into the innate immune response are crucial for developing more potent treatments for brain tumors. Our review provides a brief overview of innate immunity. In addition, we provide a discussion of current therapies aimed at boosting the innate immunity in gliomas. These approaches encompass strategies to activate Toll-like receptors, induce stress responses, enhance the innate immune response, leverage interferon type-I therapy, therapeutic antibodies, immune checkpoint antibodies, natural killer (NK) cells, and oncolytic virotherapy, and manipulate the microbiome. Both preclinical and clinical studies indicate that a better understanding of the mechanisms governing the innate immune response in GBM could enhance immunotherapy and reinforce the effects of chemotherapy and radiotherapy. Consequently, a more comprehensive understanding of the innate immune response against cancer should lead to better prognoses and increased overall survival for GBM patients.https://www.mdpi.com/1422-0067/25/2/947innate immunitygliomaimmunotherapyadaptive therapyvirotherapy |
| spellingShingle | Andrew G. Gillard Dong Ho Shin Lethan A. Hampton Andres Lopez-Rivas Akhila Parthasarathy Juan Fueyo Candelaria Gomez-Manzano Targeting Innate Immunity in Glioma Therapy International Journal of Molecular Sciences innate immunity glioma immunotherapy adaptive therapy virotherapy |
| title | Targeting Innate Immunity in Glioma Therapy |
| title_full | Targeting Innate Immunity in Glioma Therapy |
| title_fullStr | Targeting Innate Immunity in Glioma Therapy |
| title_full_unstemmed | Targeting Innate Immunity in Glioma Therapy |
| title_short | Targeting Innate Immunity in Glioma Therapy |
| title_sort | targeting innate immunity in glioma therapy |
| topic | innate immunity glioma immunotherapy adaptive therapy virotherapy |
| url | https://www.mdpi.com/1422-0067/25/2/947 |
| work_keys_str_mv | AT andrewggillard targetinginnateimmunityingliomatherapy AT donghoshin targetinginnateimmunityingliomatherapy AT lethanahampton targetinginnateimmunityingliomatherapy AT andreslopezrivas targetinginnateimmunityingliomatherapy AT akhilaparthasarathy targetinginnateimmunityingliomatherapy AT juanfueyo targetinginnateimmunityingliomatherapy AT candelariagomezmanzano targetinginnateimmunityingliomatherapy |